Context Therapeutics® Announces Pricing of Initial Public Offering
October 19 2021 - 7:14PM
Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s
oncology company developing advanced small molecule and
immunotherapy treatments to transform care for hormone-driven
breast and gynecological cancers, today announced the pricing of
its initial public offering of 5,000,000 shares of its common stock
at a public offering price of $5.00 per share, for gross proceeds
of $25.0 million, before deducting underwriting discounts,
commissions and offering expenses. In addition, the Company has
granted the underwriter a 45-day option to purchase up to an
additional 750,000 shares of common stock at the initial public
offering price, less the underwriting discount and commissions, to
cover over-allotments.
The shares are expected to begin trading on the Nasdaq Capital
Market on October 20, 2021, under the ticker symbol “CNTX”. The
offering is expected to close on October 22, 2021, subject to
satisfaction of customary closing conditions.
ThinkEquity is acting as sole book-running manager for the
offering.
A registration statement on Form S-1 (File No. 333-256572)
relating to the shares was filed with the Securities and Exchange
Commission (“SEC”) and became effective on October 19, 2021. This
offering is being made only by means of a prospectus. Copies of the
final prospectus, when available, may be obtained from ThinkEquity,
17 State Street, 22nd Floor, New York, New York 10004, by telephone
at (877) 436-3673, by email
at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Context TherapeuticsContext Therapeutics
Inc. is a women’s oncology company developing advanced small
molecule and immunotherapy treatments to transform care for
hormone-driven breast and gynecological cancers. The Company’s
robust clinical program for lead candidate onapristone extended
release (ONA-XR) comprises three Phase 2 clinical trials and one
Phase 1b/2 clinical trial in hormone-driven breast, ovarian and
endometrial cancer, as well as two Phase 0 biomarker
pharmacodynamic trials in breast cancer. ONA-XR is a novel small
molecule under development as a complete antagonist of the
progesterone receptor, a key unchecked mechanism in hormone-driven
women’s cancers. The Company is headquartered in Philadelphia,
PA.
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2024 to Jun 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2023 to Jun 2024